Generic Revlimid exclusivity loss
Revlimid exclusivity ends in FY26, which will compress revenue and margins in the U.S. business.
CIPLA / Q4-FY25 / risks
Keep the risk register visible.
Cipla · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Lanreotide supply normalization uncertainty
While supplies are resuming, the timeline to regain previous market share is uncertain and may take time.
U.S. tariff and regulatory risks
Potential U.S. tariffs on pharma imports and executive orders on pricing could impact the business, though management sees limited near-term impact.
Execution risk on peptide and respiratory pipeline
Delays in approvals or commercial launches of key pipeline assets (peptides, Advair) could affect growth trajectory.